1. Production of hyperimmune anti-SARS-CoV-2 intravenous immunoglobulin from pooled COVID-19 convalescent plasma
- Author
-
Rashid Ali, Elisha Shalim, Fatima Anjum, Syed Muneeb Uddin, Mujtaba Khan, Shaukat Ali, Abdul Samad Khan, Shobha Luxmi, Ayesha Haider Ali, Sheikh Muhammad Muhaymin, Iqra Ahmed, Saeed Quraishy, and Uzma Bukhari
- Subjects
0301 basic medicine ,Convalescent plasma ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Immunology ,intravenous immunoglobulins ,Chemical Fractionation ,diafiltration ,Antibodies, Viral ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,hemic and lymphatic diseases ,Humans ,Immunology and Allergy ,Medicine ,030212 general & internal medicine ,COVID-19 Serotherapy ,biology ,SARS-CoV-2 ,business.industry ,caprylic acid ,pooled plasma ,Caprylic acid ,Immunization, Passive ,anti-COVID-19 IVIG ,COVID-19 ,Immunoglobulins, Intravenous ,Diafiltration ,Titer ,030104 developmental biology ,Oncology ,Immunization ,chemistry ,convalescent plasma ,ultrafiltration ,biology.protein ,passive immunization ,immunotherapy ,Caprylates ,Antibody ,business ,Research Article - Abstract
Background: This study assesses the feasibility of producing hyperimmune anti-COVID-19 intravenously administrable immunoglobulin (C-IVIG) from pooled convalescent plasma (PCP) to provide a safe and effective passive immunization treatment option for COVID-19. Materials & methods: PCP was fractionated by modified caprylic acid precipitation followed by ultrafiltration/diafiltration to produce hyperimmune C-IVIG. Results: In C-IVIG, the mean SARS-CoV-2 antibody level was found to be threefold (104 ± 30 cut-off index) that of the PCP (36 ± 8.5 cut-off index) and mean protein concentration was found to be 46 ± 3.7 g/l, comprised of 89.5% immunoglobulins. Conclusion: The current method of producing C-IVIG is feasible as it uses locally available PCP and simpler technology and yields a high titer of SARS-CoV-2 antibody. The safety and efficacy of C-IVIG will be evaluated in a registered clinical trial (NCT 04521309).
- Published
- 2021